KYVERNA THERAPEUTICS INC (KYTX) Stock News

USA - NASDAQ:KYTX - US5019761049 - Common Stock

6.9 USD

+0.42 (+6.48%)

Last: 11/14/2025, 10:01:50 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KYTX Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

2 days ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

4 days ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

10 days ago - By: Benzinga - Mentions: QURE RCKT CABA NGNE

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

4 months ago - By: Kyverna Therapeutics

News Image

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

11 days ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

16 days ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

16 days ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

20 days ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

20 days ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

23 days ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

23 days ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

a month ago - By: Bragar Eagel & Squire

KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

2 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

2 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

2 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

2 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

3 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

3 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

3 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

3 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

3 months ago - By: Benzinga

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

3 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

3 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

4 months ago - By: Yahoo Finance - Mentions: ALEC

Kyverna Appoints New CFO to Guide Next Growth Phase

4 months ago - By: Bragar Eagel & Squire

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

6 months ago - By: Kyverna Therapeutics

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

6 months ago - By: Bragar Eagel & Squire

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

6 months ago - By: Kyverna Therapeutics

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

7 months ago - By: Grabar Law Office - Mentions: MEI MODV MPWR

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your

8 months ago - By: Grabar Law Office - Mentions: HLLY IART VIRT

ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT)

8 months ago - By: Kyverna Therapeutics

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

8 months ago - By: Grabar Law Office - Mentions: AKRO DRVN IART

Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is

8 months ago - By: Grabar Law Office - Mentions: DRVN MRCY RKLB

Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your

8 months ago - By: Grabar Law Office - Mentions: ADM DRVN MRCY

Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your